Monitor for HKEX waiver announcement and any subsequent ATM sales. If the program activates, expect incremental dilution pressure on ADS price. The company's cash runway may extend if the full $200M is raised, but near-term stock reaction likely muted until actual sales commence.
Price Chart
Executive Summary
Ascentage Pharma filed a 6-K announcing a proposed at-the-market (ATM) offering of up to $200 million in ADSs via an automatic shelf registration on Form F-3, contingent on Hong Kong Stock Exchange waivers. The proceeds are intended to fund commercialization of olverembatinib and lisaftoclax, ongoing trials, and working capital. The offering has not yet commenced and remains subject to regulatory approvals.
Key Facts
- Proposed ATM program for up to $200 million of ADSs
- Filed automatic shelf registration on Form F-3 (333-297559)
- Sales agents: Citigroup, Deutsche Bank, BTIG
- Net proceeds to fund commercialization of olverembatinib and lisaftoclax, clinical trials, and working capital
- No sales until HK Listing Rules waivers are granted; waiver application pending
- ATM sales to occur only outside blackout periods and when no material nonpublic information exists
Financial Impact
Maximum gross proceeds of $200 million, representing approximately 11.8% of current market cap ($1.7B), but actual sales are not yet determinable and may be lower.
Risk Factors
- Dilution from potential ADS issuance over time
- HKEX waivers may not be granted, delaying or preventing the program
- Use of proceeds broad and management retains discretion
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-079420 |
| Document: ea0298534-6k_ascentage.htm | 0001213900-26-079420 |
| Document: 0001213900-26-079420-index-headers.html | 0001213900-26-079420 |
| Document: 0001213900-26-079420-index.html | 0001213900-26-079420 |
| Document: 0001213900-26-079420.txt | 0001213900-26-079420 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $15.44 $15.45 | ▲ +0.06% | ▼ −0.65% | $14.85 (−3.82%) |
Oct 21, 2026 6d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $14.85 (−0.47%) |
Oct 15, 2026 12d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $14.85 (+1.09%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $14.85 (+3.38%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $14.85 (+14.26%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $14.85 (−11.90%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $14.85 (−11.63%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $14.85 (−21.39%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $14.85 (−19.16%) |
Jul 13, 2026 15w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $14.85 (−22.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers